(Q28166089)

https://api.crossref.org/works/10.1097/00055735-200312000-00012

1 April 2024

2

David Sarraf

0 references

author name string

Atul Jain

1

0 references

Donald Fong

full work available at URL

3

0 references

language of work or name

English

0 references

publication date

December 2003

0 references

https://journals.lww.com/00055735-200312000-00012

1 reference

https://api.crossref.org/works/10.1097/00055735-200312000-00012

Current Opinion in Ophthalmology

1 April 2024

published in

0 references

volume

14

0 references

issue

6

0 references

page(s)

389-94

0 references

cites work

The Wisconsin epidemiologic study of diabetic retinopathy. II. Prevalence and risk of diabetic retinopathy when age at diagnosis is less than 30 years

1

1 reference

https://api.crossref.org/works/10.1097/00055735-200312000-00012

The Wisconsin epidemiologic study of diabetic retinopathy. III. Prevalence and risk of diabetic retinopathy when age at diagnosis is 30 or more years

1 April 2024

2

1 reference

https://api.crossref.org/works/10.1097/00055735-200312000-00012

The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group

1 April 2024

4

1 reference

https://api.crossref.org/works/10.1097/00055735-200312000-00012

Progression of retinopathy with intensive versus conventional treatment in the Diabetes Control and Complications Trial. Diabetes Control and Complications Trial Research Group

1 April 2024

5

1 reference

https://api.crossref.org/works/10.1097/00055735-200312000-00012

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group

1 April 2024

6

1 reference

https://api.crossref.org/works/10.1097/00055735-200312000-00012

Retinopathy and nephropathy in patients with type 1 diabetes four years after a trial of intensive therapy

1 April 2024

7

1 reference

https://api.crossref.org/works/10.1097/00055735-200312000-00012

Risk factors for incident retinopathy in a diabetic and nondiabetic population: the Hoorn study

1 April 2024

8

1 reference

https://api.crossref.org/works/10.1097/00055735-200312000-00012

Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group

1 April 2024

9

1 reference

https://api.crossref.org/works/10.1097/00055735-200312000-00012

Systemic considerations in the management of diabetic retinopathy

1 April 2024

10

1 reference

https://api.crossref.org/works/10.1097/00055735-200312000-00012

Blood pressure control and diabetic retinopathy

1 April 2024

13

1 reference

https://api.crossref.org/works/10.1097/00055735-200312000-00012

The Natural Course of Microalbuminuria in Insulin‐dependent Diabetes: A 10‐year Prospective Study

1 April 2024

16

1 reference

https://api.crossref.org/works/10.1097/00055735-200312000-00012

The Wisconsin Epidemiologic Study of Diabetic Retinopathy: XVII. The 14-year incidence and progression of diabetic retinopathy and associated risk factors in type 1 diabetes

1 April 2024

17

1 reference

https://api.crossref.org/works/10.1097/00055735-200312000-00012

Angiotensin-converting enzyme inhibition for the treatment of moderate to severe diabetic retinopathy in normotensive Type 2 diabetic patients. A pilot study

1 April 2024

18

1 reference

https://api.crossref.org/works/10.1097/00055735-200312000-00012

Angiotensin converting enzyme inhibiting therapy is associated with lower vitreous vascular endothelial growth factor concentrations in patients with proliferative diabetic retinopathy

1 April 2024

19

1 reference

https://api.crossref.org/works/10.1097/00055735-200312000-00012

Circulating plasma vascular endothelial growth factor and microvascular complications of type 1 diabetes mellitus: the influence of ACE inhibition

1 April 2024

20

1 reference

https://api.crossref.org/works/10.1097/00055735-200312000-00012

Effect of lisinopril on progression of retinopathy in normotensive people with type 1 diabetes. The EUCLID Study Group. EURODIAB Controlled Trial of Lisinopril in Insulin-Dependent Diabetes Mellitus

1 April 2024

21

1 reference

https://api.crossref.org/works/10.1097/00055735-200312000-00012

1 April 2024

Annals of ophthalmology

22

25

284

Chase

1993

1 reference

https://api.crossref.org/works/10.1097/00055735-200312000-00012

Protective effect of captopril on the blood-retina barrier in normotensive insulin-dependent diabetic patients with nephropathy and background retinopathy

1 April 2024

23

1 reference

https://api.crossref.org/works/10.1097/00055735-200312000-00012

Main risk factors for nephropathy in type 2 diabetes mellitus are plasma cholesterol levels, mean blood pressure, and hyperglycemia.

1 April 2024

24

1 reference

https://api.crossref.org/works/10.1097/00055735-200312000-00012

The role of serum lipids in exudative diabetic maculopathy: is there a place for lipid lowering therapy?

1 April 2024

25

1 reference

https://api.crossref.org/works/10.1097/00055735-200312000-00012

A double-blind controlled trial of clofibrate in the treatment of diabetic retinopathy

1 April 2024

26

1 reference

https://api.crossref.org/works/10.1097/00055735-200312000-00012

Transactions of the ophthalmological societies of the United Kingdom

1 April 2024

27

84

281

Cullen

1964

1 reference

https://api.crossref.org/works/10.1097/00055735-200312000-00012

A three-year trial of atromid therapy in exudative diabetic retinopathy

1 April 2024

28

1 reference

https://api.crossref.org/works/10.1097/00055735-200312000-00012

Association of elevated serum lipid levels with retinal hard exudate in diabetic retinopathy. Early Treatment Diabetic Retinopathy Study (ETDRS) Report 22.

1 April 2024

29

1 reference

https://api.crossref.org/works/10.1097/00055735-200312000-00012

Subretinal fibrosis in diabetic macular edema. ETDRS report 23. Early Treatment Diabetic Retinopathy Study Research Group

1 April 2024

30

1 reference

https://api.crossref.org/works/10.1097/00055735-200312000-00012

Aspirin in diabetic retinopathy. A systematic review

1 April 2024

31

1 reference

https://api.crossref.org/works/10.1097/00055735-200312000-00012

Pharmacological inhibition of diabetic retinopathy: aminoguanidine and aspirin

1 April 2024

32

1 reference

https://api.crossref.org/works/10.1097/00055735-200312000-00012

Cigarette smoking and ten-year progression of diabetic retinopathy

1 April 2024

34

1 reference

https://api.crossref.org/works/10.1097/00055735-200312000-00012

Cigarette smoking and progression of retinopathy and nephropathy in type 1 diabetes

1 April 2024

35

1 reference

https://api.crossref.org/works/10.1097/00055735-200312000-00012

Smoking and the genetics of signal transduction: an association study on retinopathy in type 1 diabetes

1 April 2024

36

1 reference

https://api.crossref.org/works/10.1097/00055735-200312000-00012

Cigarette smoking and ten-year progression of diabetic retinopathy

1 April 2024

37

1 reference

https://api.crossref.org/works/10.1097/00055735-200312000-00012

The Effect of Pregnancy on the Natural Course of Diabetic Retinopathy

1 April 2024

38

1 reference

https://api.crossref.org/works/10.1097/00055735-200312000-00012

Effect of pregnancy on progression of diabetic retinopathy

1 April 2024

39

1 reference

https://api.crossref.org/works/10.1097/00055735-200312000-00012

Effect of pregnancy on microvascular complications in the diabetes control and complications trial. The Diabetes Control and Complications Trial Research Group

1 April 2024

40

1 reference

https://api.crossref.org/works/10.1097/00055735-200312000-00012

Retinal capillary blood flow in diabetic and nondiabetic women during pregnancy and postpartum period

1 April 2024

41

1 reference

https://api.crossref.org/works/10.1097/00055735-200312000-00012

Investigative Ophthalmology Visual Science

1 April 2024

42

35

3199

Chen

1994

1 reference

https://api.crossref.org/works/10.1097/00055735-200312000-00012

The effect of pregnancy on retinal hemodynamics in diabetic versus nondiabetic mothers

1 April 2024

43

1 reference

https://api.crossref.org/works/10.1097/00055735-200312000-00012

Progesterone induces vascular endothelial growth factor on retinal pigment epithelial cells in culture

1 April 2024

44

1 reference

https://api.crossref.org/works/10.1097/00055735-200312000-00012

Metabolic control and progression of retinopathy. The Diabetes in Early Pregnancy Study. National Institute of Child Health and Human Development Diabetes in Early Pregnancy Study

1 April 2024

45

1 reference

https://api.crossref.org/works/10.1097/00055735-200312000-00012

Does pregnancy accelerate the rate of progression of diabetic retinopathy?

1 April 2024

46

1 reference

https://api.crossref.org/works/10.1097/00055735-200312000-00012

Progression of retinopathy during pregnancy in type 1 diabetic women treated with insulin lispro

1 April 2024

47

1 reference

https://api.crossref.org/works/10.1097/00055735-200312000-00012

The Relationship Between Pregnancy and Long‐term Maternal Complications in the EURODIAB IDDM Complications Study

1 April 2024

48

1 reference

https://api.crossref.org/works/10.1097/00055735-200312000-00012

Familial clustering of diabetic retinopathy in South Indian Type 2 diabetic patients

1 April 2024

49

1 reference

https://api.crossref.org/works/10.1097/00055735-200312000-00012

Human lymphocyte antigen DR7 protects against proliferative retinopathy with type II diabetes mellitus

1 April 2024

50

1 reference

https://api.crossref.org/works/10.1097/00055735-200312000-00012

Intercellular adhesion molecule-1 (ICAM-1) polymorphism is associated with diabetic retinopathy in Type 2 diabetes mellitus

1 April 2024

52

1 reference

https://api.crossref.org/works/10.1097/00055735-200312000-00012

Polymorphism R25P in the gene encoding transforming growth factor-beta (TGF-beta1) is a newly identified risk factor for proliferative diabetic retinopathy

1 April 2024

53

1 reference

https://api.crossref.org/works/10.1097/00055735-200312000-00012

1 April 2024

Identifiers